Conserved herpesvirus protein kinases

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1784, Issue 1, 2008, Pages 203-212

  Gershburg, Edward ^a,b,c,d   Pagano, Joseph S ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c Cell Biology   (United States)

^d SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiviral compound; Herpesvirus; Protein kinase; Protein kinase inhibitor; Serine Threonine kinase

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; BENZIMIDAVIR; CARBAZOLE DERIVATIVE; CIDOFOVIR; CONSERVED HERPES VIRUS PROTEIN KINASE; CONSERVED HERPES VIRUS PROTEIN KINASE INHIBITOR; GEFITINIB; INDOLOCARBAZOLE DERIVATIVE; PROTEIN KINASE; PROTEIN KINASE BGL4; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; QUINAZOLINE DERIVATIVE; UL97 ANTIBODY; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS PROTEIN ORF47;

ARTICLE; CYTOMEGALOVIRUS; DRUG EFFICACY; ENZYME ANALYSIS; EPSTEIN BARR VIRUS; HERPES VIRUS; INDIVIDUALIZATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATORY MECHANISM; SEQUENCE HOMOLOGY; STRUCTURE ACTIVITY RELATION; VIRUS INFECTION;

ANTIVIRAL AGENTS; HERPESVIRIDAE; HERPESVIRIDAE INFECTIONS; HUMANS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; VIRAL PROTEINS;

HERPESVIRIDAE; HUMAN HERPESVIRUS 4; HUMAN HERPESVIRUS 5;

EID: 38149065307     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2007.08.009     Document Type: Article

References (122)

1. De Clercq E., Brancale A., Hodge A.V., and Field H.J. Antiviral chemistry & chemotherapy's current antiviral agents FactFile 2006 (1st edition). Antivir. Chem. Chemother. 17 (2006) 113-166
2. De Clercq E. Antiviral drugs in current clinical use. J. Clin. Virol. 30 (2004) 115-133
3. Pellett P.E., and Roizman B. Fields virology. In: Knipe D.M., Howley P.M., Griffin D.E., Lamb R.A., Martin M.A., and Roizman B. (Eds) (2007), Lippincott Williams & Wilkins 2479-2500
4. Chee M.S., Lawrence G.L., and Barrell B.G. Alpha-, beta- and gammaherpesviruses encode a putative phosphotransferase. J. Gen. Virol. 70 Pt 5 (1989) 1151-1160
5. Smith R.F., and Smith T.F. Identification of new protein kinase-related genes in three herpesviruses, herpes simplex virus, varicella-zoster virus, and Epstein-Barr virus. J. Virol. 63 (1989) 450-455
6. Ng T.I., and Grose C. Serine protein kinase associated with varicella-zoster virus ORF 47. Virology 191 (1992) 9-18
7. Chen M.R., Chang S.J., Huang H., and Chen J.Y. A protein kinase activity associated with Epstein-Barr virus BGLF4 phosphorylates the viral early antigen EA-D in vitro. J. Virol. 74 (2000) 3093-3104
8. Gershburg E., and Pagano J.S. Phosphorylation of the Epstein-Barr virus (EBV) DNA polymerase processivity factor EA-D by the EBV-encoded protein kinase and effects of the l-riboside benzimidazole 1263W94. J. Virol. 76 (2002) 998-1003
9. Littler E., Stuart A.D., and Chee M.S. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 358 (1992) 160-162
10. Sullivan V., Talarico C.L., Stanat S.C., Davis M., Coen D.M., and Biron K.K. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 358 (1992) 162-164
11. He Z., He Y.S., Kim Y., Chu L., Ohmstede C., Biron K.K., and Coen D.M. The human cytomegalovirus UL97 protein is a protein kinase that autophosphorylates on serines and threonines. J. Virol. 71 (1997) 405-411
12. Ansari A., and Emery V.C. The U69 gene of human herpesvirus 6 encodes a protein kinase which can confer ganciclovir sensitivity to baculoviruses. J. Virol. 73 (1999) 3284-3291
13. Park J., Lee D., Seo T., Chung J., and Choe J. Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) open reading frame 36 protein is a serine protein kinase. J. Gen. Virol. 81 (2000) 1067-1071
14. de Wind N., Domen J., and Berns A. Herpesviruses encode an unusual protein-serine/threonine kinase which is nonessential for growth in cultured cells. J. Virol. 66 (1992) 5200-5209
15. Coulter L.J., Moss H.W., Lang J., and McGeoch D.J. A mutant of herpes simplex virus type 1 in which the UL13 protein kinase gene is disrupted. J. Gen. Virol. 74 (1993) 387-395
16. Tanaka M., Nishiyama Y., Sata T., and Kawaguchi Y. The role of protein kinase activity expressed by the UL13 gene of herpes simplex virus 1: the activity is not essential for optimal expression of UL41 and ICP0. Virology 341 (2005) 301-312
17. Purves F.C., Ogle W.O., and Roizman B. Processing of the herpes simplex virus regulatory protein alpha 22 mediated by the UL13 protein kinase determines the accumulation of a subset of alpha and gamma mRNAs and proteins in infected cells. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 6701-6705
18. Kato A., Yamamoto M., Ohno T., Tanaka M., Sata T., Nishiyama Y., and Kawaguchi Y. Herpes simplex virus 1-encoded protein kinase UL13 phosphorylates viral Us3 protein kinase and regulates nuclear localization of viral envelopment factors UL34 and UL31. J. Virol. 80 (2006) 1476-1486
19. Wagenaar F., Pol J.M., Peeters B., Gielkens A.L., de Wind N., and Kimman T.G. The US3-encoded protein kinase from pseudorabies virus affects egress of virions from the nucleus. J. Gen. Virol. 76 Pt 7 (1995) 1851-1859
20. Klupp B.G., Granzow H., and Mettenleiter T.C. Effect of the pseudorabies virus US3 protein on nuclear membrane localization of the UL34 protein and virus egress from the nucleus. J. Gen. Virol. 82 (2001) 2363-2371
21. Morrison E.E., Wang Y.F., and Meredith D.M. Phosphorylation of structural components promotes dissociation of the herpes simplex virus type 1 tegument. J. Virol. 72 (1998) 7108-7114
22. Daikoku T., Shibata S., Goshima F., Oshima S., Tsurumi T., Yamada H., Yamashita Y., and Nishiyama Y. Purification and characterization of the protein kinase encoded by the UL13 gene of herpes simplex virus type 2. Virology 235 (1997) 82-93
23. Kenyon T.K., Lynch J., Hay J., Ruyechan W., and Grose C. Varicella-zoster virus ORF47 protein serine kinase: characterization of a cloned, biologically active phosphotransferase and two viral substrates, ORF62 and ORF63. J. Virol. 75 (2001) 8854-8858
24. Kinchington P.R., Fite K., and Turse S.E. Nuclear accumulation of IE62, the varicella-zoster virus (VZV) major transcriptional regulatory protein, is inhibited by phosphorylation mediated by the VZV open reading frame 66 protein kinase. J. Virol. 74 (2000) 2265-2277
25. Ng T.I., Keenan L., Kinchington P.R., and Grose C. Phosphorylation of varicella-zoster virus open reading frame (ORF) 62 regulatory product by viral ORF 47-associated protein kinase. J. Virol. 68 (1994) 1350-1359
26. Kenyon T.K., Cohen J.I., and Grose C. Phosphorylation by the varicella-zoster virus ORF47 protein serine kinase determines whether endocytosed viral gE traffics to the trans-Golgi network or recycles to the cell membrane. J. Virol. 76 (2002) 10980-10993
27. Spengler M., Niesen N., Grose C., Ruyechan W.T., and Hay J. Interactions among structural proteins of varicella zoster virus. Arch. Virol., Suppl. (2001) 71-79
28. Reddy S.M., Cox E., Iofin I., Soong W., and Cohen J.I. Varicella-zoster virus (VZV) ORF32 encodes a phosphoprotein that is posttranslationally modified by the VZV ORF47 protein kinase. J. Virol. 72 (1998) 8083-8088
29. Mo C., Lee J., Sommer M., Grose C., and Arvin A.M. The requirement of varicella zoster virus glycoprotein E (gE) for viral replication and effects of glycoprotein I on gE in melanoma cells. Virology 304 (2002) 176-186
30. Heineman T.C., and Cohen J.I. The varicella-zoster virus (VZV) open reading frame 47 (ORF47) protein kinase is dispensable for viral replication and is not required for phosphorylation of ORF63 protein, the VZV homolog of herpes simplex virus ICP22. J. Virol. 69 (1995) 7367-7370
31. Moffat J.F., Zerboni L., Sommer M.H., Heineman T.C., Cohen J.I., Kaneshima H., and Arvin A.M. The ORF47 and ORF66 putative protein kinases of varicella-zoster virus determine tropism for human T cells and skin in the SCID-hu mouse. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 11969-11974
32. Hu H., and Cohen J.I. Varicella-zoster virus open reading frame 47 (ORF47) protein is critical for virus replication in dendritic cells and for spread to other cells. Virology 337 (2005) 304-311
33. Rahaus M., Desloges N., and Wolff M.H. Varicella-zoster virus requires a functional PI3K/Akt/GSK-3alpha/beta signaling cascade for efficient replication. Cell. Signal. 19 (2007) 312-320
34. Koyano S., Suzutani T., Yoshida I., and Azuma M. Analysis of phosphorylation pathways of antiherpesvirus nucleosides by varicella-zoster virus-specific enzymes. Antimicrob. Agents Chemother. 40 (1996) 920-923
35. Suzutani T., Ogasawara M., Shibaki T., and Azuma M. Susceptibility of protein kinase (ORF47)-deficient varicella-zoster virus strains to anti-herpesvirus nucleosides. Antivir. Res. 45 (2000) 79-82
36. Michel D., Pavic I., Zimmermann A., Haupt E., Wunderlich K., Heuschmid M., and Mertens T. The UL97 gene product of human cytomegalovirus is an early-late protein with a nuclear localization but is not a nucleoside kinase. J. Virol. 70 (1996) 6340-6346
37. van Zeijl M., Fairhurst J., Baum E.Z., Sun L., and Jones T.R. The human cytomegalovirus UL97 protein is phosphorylated and a component of virions. Virology 231 (1997) 72-80
38. Wolf D.G., Honigman A., Lazarovits J., Tavor E., and Panet A. Characterization of the human cytomegalovirus UL97 gene product as a virion-associated protein kinase. Arch. Virol. 143 (1998) 1223-1232
39. Prichard M.N., Gao N., Jairath S., Mulamba G., Krosky P., Coen D.M., Parker B.O., and Pari G.S. A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency. J. Virol. 73 (1999) 5663-5670
40. Romaker D., Schregel V., Maurer K., Auerochs S., Marzi A., Sticht H., and Marschall M. Analysis of the structure-activity relationship of four herpesviral UL97 subfamily protein kinases reveals partial but not full functional conservation. J. Med. Chem. 49 (2006) 7044-7053
41. Krosky P.M., Baek M.C., Jahng W.J., Barrera I., Harvey R.J., Biron K.K., Coen D.M., and Sethna P.B. The human cytomegalovirus UL44 protein is a substrate for the UL97 protein kinase. J. Virol. 77 (2003) 7720-7727
42. Marschall M., Freitag M., Suchy P., Romaker D., Kupfer R., Hanke M., and Stamminger T. The protein kinase pUL97 of human cytomegalovirus interacts with and phosphorylates the DNA polymerase processivity factor pUL44. Virology 311 (2003) 60-71
43. Wolf D.G., Courcelle C.T., Prichard M.N., and Mocarski E.S. Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 1895-1900
44. Baek M.C., Krosky P.M., Pearson A., and Coen D.M. Phosphorylation of the RNA polymerase II carboxyl-terminal domain in human cytomegalovirus-infected cells and in vitro by the viral UL97 protein kinase. Virology 324 (2004) 184-193
45. Kawaguchi Y., Kato K., Tanaka M., Kanamori M., Nishiyama Y., and Yamanashi Y. Conserved protein kinases encoded by herpesviruses and cellular protein kinase cdc2 target the same phosphorylation site in eukaryotic elongation factor 1delta. J. Virol. 77 (2003) 2359-2368
46. Krosky P.M., Baek M.C., and Coen D.M. The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J. Virol. 77 (2003) 905-914
47. Marschall M., Marzi A., aus dem Siepen P., Jochmann R., Kalmer M., Auerochs S., Lischka P., Leis M., and Stamminger T. Cellular p32 recruits cytomegalovirus kinase pUL97 to redistribute the nuclear lamina. J. Biol. Chem. 280 (2005) 33357-33367
48. W.T. Seaman, E. Holley-Guthrie, E. Gershburg, S.J. Dickerson, H.-J. Delecluse, J.S. Pagano and S.C. Kenney, BMRF1 transcriptional function, but not phosphorylation by the BGLF4-encoded protein kinase, is important for Epstein-Barr virus replication, submitted for publication.
49. Prichard M.N., Britt W.J., Daily S.L., Hartline C.B., and Kern E.R. Human cytomegalovirus UL97 Kinase is required for the normal intranuclear distribution of pp65 and virion morphogenesis. J. Virol. 79 (2005) 15494-15502
50. Azzeh M., Honigman A., Taraboulos A., Rouvinski A., and Wolf D.G. Structural changes in human cytomegalovirus cytoplasmic assembly sites in the absence of UL97 kinase activity. Virology 354 (2006) 69-79
51. Baek M.C., Krosky P.M., and Coen D.M. Relationship between autophosphorylation and phosphorylation of exogenous substrates by the human cytomegalovirus UL97 protein kinase. J. Virol. 76 (2002) 11943-11952
52. Baek M.C., Krosky P.M., He Z., and Coen D.M. Specific phosphorylation of exogenous protein and peptide substrates by the human cytomegalovirus UL97 protein kinase. Importance of the P + 5 position. J. Biol. Chem. 277 (2002) 29593-29599
53. Talarico C.L., Burnette T.C., Miller W.H., Smith S.L., Davis M.G., Stanat S.C., Ng T.I., He Z., Coen D.M., Roizman B., and Biron K.K. Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein. Antimicrob. Agents Chemother. 43 (1999) 1941-1946
54. Michel D., Kramer S., Hohn S., Schaarschmidt P., Wunderlich K., and Mertens T. Amino acids of conserved kinase motifs of cytomegalovirus protein UL97 are essential for autophosphorylation. J. Virol. 73 (1999) 8898-8901
55. Gompels U.A., Nicholas J., Lawrence G., Jones M., Thomson B.J., Martin M.E., Efstathiou S., Craxton M., and Macaulay H.A. The DNA sequence of human herpesvirus-6: structure, coding content, and genome evolution. Virology 209 (1995) 29-51
56. De Bolle L., Michel D., Mertens T., Manichanh C., Agut H., De Clercq E., and Naesens L. Role of the human herpesvirus 6 U69-encoded kinase in the phosphorylation of ganciclovir. Mol. Pharmacol. 62 (2002) 714-721
57. Manichanh C., Olivier-Aubron C., Lagarde J.P., Aubin J.T., Bossi P., Gautheret-Dejean A., Huraux J.M., and Agut H. Selection of the same mutation in the U69 protein kinase gene of human herpesvirus-6 after prolonged exposure to ganciclovir in vitro and in vivo. J. Gen. Virol. 82 (2001) 2767-2776
58. Safronetz D., Petric M., Tellier R., Parvez B., and Tipples G.A. Mapping ganciclovir resistance in the human herpesvirus-6 U69 protein kinase. J. Med. Virol. 71 (2003) 434-439
59. Gershburg E., Marschall M., Hong K., and Pagano J.S. Expression and localization of the Epstein-Barr virus-encoded protein kinase. J. Virol. 78 (2004) 12140-12146
60. Wang J.T., Yang P.W., Lee C.P., Han C.H., Tsai C.H., and Chen M.R. Detection of Epstein-Barr virus BGLF4 protein kinase in virus replication compartments and virus particles. J. Gen. Virol. 86 (2005) 3215-3225
61. Gershburg E., Raffa S., Torrisi M.R., and Pagano J.S. Epstein-Barr virus-encoded protein kinase (BGLF4) is involved in production of infectious virus. J. Virol. 81 (2007) 5407-5412
62. Gonnella R., Farina A., Santarelli R., Raffa S., Feederle R., Bei R., Granato M., Modesti A., Frati L., Delecluse H.J., Torrisi M.R., Angeloni A., and Faggioni A. Characterization and intracellular localization of the Epstein-Barr virus protein BFLF2: interactions with BFRF1 and with the nuclear lamina. J. Virol. 79 (2005) 3713-3727
63. Lee C.P., Chen J.Y., Wang J.T., Kimura K., Takemoto A., Lu C.C., and Chen M.R. EBV BGLF4 kinase induces premature chromosome condensation through activation of condensin and topoisomerase II. J. Virol. 81 (2007) 5166-5180
64. Kudoh A., Daikoku T., Ishimi Y., Kawaguchi Y., Shirata N., Iwahori S., Isomura H., and Tsurumi T. Phosphorylation of MCM4 at sites inactivating DNA helicase activity of the MCM4-MCM6-MCM7 complex during Epstein-Barr virus productive replication. J. Virol. 80 (2006) 10064-10072
65. Asai R., Kato A., Kato K., Kanamori-Koyama M., Sugimoto K., Sairenji T., Nishiyama Y., and Kawaguchi Y. Epstein-Barr virus protein kinase BGLF4 is a virion tegument protein that dissociates from virions in a phosphorylation-dependent process and phosphorylates the viral immediate-early protein BZLF1. J. Virol. 80 (2006) 5125-5134
66. Kato K., Yokoyama A., Tohya Y., Akashi H., Nishiyama Y., and Kawaguchi Y. Identification of protein kinases responsible for phosphorylation of Epstein-Barr virus nuclear antigen leader protein at serine-35, which regulates its coactivator function. J. Gen. Virol. 84 (2003) 3381-3392
67. Yue W., Gershburg E., and Pagano J.S. Hyperphosphorylation of EBNA2 by Epstein-Barr virus protein kinase suppresses transactivation of the LMP1 promoter. J. Virol. 79 (2005) 5880-5885
68. Gershburg E., Hong K., and Pagano J.S. Effects of maribavir and selected indolocarbazoles on Epstein-Barr virus protein kinase BGLF4 and on viral lytic replication. Antimicrob. Agents Chemother. 48 (2004) 1900-1903
69. Kato K., Kawaguchi Y., Tanaka M., Igarashi M., Yokoyama A., Matsuda G., Kanamori M., Nakajima K., Nishimura Y., Shimojima M., Phung H.T., Takahashi E., and Hirai K. Epstein-Barr virus-encoded protein kinase BGLF4 mediates hyperphosphorylation of cellular elongation factor 1delta (EF-1delta): EF-1delta is universally modified by conserved protein kinases of herpesviruses in mammalian cells. J. Gen. Virol. 82 (2001) 1457-1463
70. de Turenne-Tessier M., Ooka T., de The G., and Daillie J. Characterization of an Epstein-Barr virus-induced thymidine kinase. J. Virol. 57 (1986) 1105-1112
71. Littler E., Zeuthen J., McBride A.A., Trost Sorensen E., Powell K.L., Walsh-Arrand J.E., and Arrand J.R. Identification of an Epstein-Barr virus-coded thymidine kinase. EMBO. J. 5 (1986) 1959-1966
72. Roubal J., and Klein G. Synthesis of thymidine kinase (TK) in Epstein-Barr virus-superinfected Raji TK-negative cells. Intervirology 15 (1981) 43-48
73. Moore S.M., Cannon J.S., Tanhehco Y.C., Hamzeh F.M., and Ambinder R.F. Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues. Antimicrob. Agents Chemother. 45 (2001) 2082-2091
74. Gustafson E.A., Chillemi A.C., Sage D.R., and Fingeroth J.D. The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase. Antimicrob. Agents Chemother. 42 (1998) 2923-2931
75. Haque M., Wang V., Davis D.A., Zheng Z.M., and Yarchoan R. Genetic organization and hypoxic activation of the Kaposi's sarcoma-associated herpesvirus ORF34-37 gene cluster. J. Virol. 80 (2006) 7037-7051
76. Jenner R.G., Alba M.M., Boshoff C., and Kellam P. Kaposi's sarcoma-associated herpesvirus latent and lytic gene expression as revealed by DNA arrays. J. Virol. 75 (2001) 891-902
77. Paulose-Murphy M., Ha N.K., Xiang C., Chen Y., Gillim L., Yarchoan R., Meltzer P., Bittner M., Trent J., and Zeichner S. Transcription program of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus). J. Virol. 75 (2001) 4843-4853
78. Lu M., Suen J., Frias C., Pfeiffer R., Tsai M.H., Chuang E., and Zeichner S.L. Dissection of the Kaposi's sarcoma-associated herpesvirus gene expression program by using the viral DNA replication inhibitor cidofovir. J. Virol. 78 (2004) 13637-13652
79. Izumiya Y., Izumiya C., Van Geelen A., Wang D.H., Lam K.S., Luciw P.A., and Kung H.J. Kaposi's sarcoma-associated herpesvirus-encoded protein kinase and its interaction with K-bZIP. J. Virol. 81 (2007) 1072-1082
80. Hamza M.S., Reyes R.A., Izumiya Y., Wisdom R., Kung H.J., and Luciw P.A. ORF36 protein kinase of Kaposi's sarcoma herpesvirus activates the c-Jun N-terminal kinase signaling pathway. J. Biol. Chem. 279 (2004) 38325-38330
81. Izumiya Y., Ellison T.J., Yeh E.T., Jung J.U., Luciw P.A., and Kung H.J. Kaposi's sarcoma-associated herpesvirus K-bZIP represses gene transcription via SUMO modification. J. Virol. 79 (2005) 9912-9925
82. Adamson A.L., and Kenney S. Epstein-Barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies. J. Virol. 75 (2001) 2388-2399
83. Daibata M., Humphreys R.E., and Sairenji T. Phosphorylation of the Epstein-Barr virus BZLF1 immediate-early gene product ZEBRA. Virology 188 (1992) 916-920
84. El-Guindy A.S., Paek S.Y., Countryman J., and Miller G. Identification of constitutive phosphorylation sites on the Epstein-Barr virus ZEBRA protein. J. Biol. Chem. 281 (2006) 3085-3095
85. Kolman J.L., Taylor N., Marshak D.R., and Miller G. Serine-173 of the Epstein-Barr virus ZEBRA protein is required for DNA binding and is a target for casein kinase II phosphorylation. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 10115-10119
86. Cannon J.S., Hamzeh F., Moore S., Nicholas J., and Ambinder R.F. Human herpesvirus 8-encoded thymidine kinase and phosphotransferase homologues confer sensitivity to ganciclovir. J. Virol. 73 (1999) 4786-4793
87. Kawaguchi Y., Matsumura T., Roizman B., and Hirai K. Cellular elongation factor 1delta is modified in cells infected with representative alpha-, beta-, or gammaherpesviruses. J. Virol. 73 (1999) 4456-4460
88. Kawaguchi Y., Van Sant C., and Roizman B. Eukaryotic elongation factor 1delta is hyperphosphorylated by the protein kinase encoded by the U(L)13 gene of herpes simplex virus 1. J. Virol. 72 (1998) 1731-1736
89. Kawaguchi Y., and Kato K. Protein kinases conserved in herpesviruses potentially share a function mimicking the cellular protein kinase cdc2. Rev. Med. Virol. 13 (2003) 331-340
90. Ng T.I., Talarico C., Burnette T.C., Biron K., and Roizman B. Partial substitution of the functions of the herpes simplex virus 1 U(L)13 gene by the human cytomegalovirus U(L)97 gene. Virology 225 (1996) 347-358
91. Marschall M., Stein-Gerlach M., Freitag M., Kupfer R., van den Bogaard M., and Stamminger T. Direct targeting of human cytomegalovirus protein kinase pUL97 by kinase inhibitors is a novel principle for antiviral therapy. J. Gen. Virol. 83 (2002) 1013-1023
92. Metzger C., Michel D., Schneider K., Luske A., Schlicht H.J., and Mertens T. Human cytomegalovirus UL97 kinase confers ganciclovir susceptibility to recombinant vaccinia virus. J. Virol. 68 (1994) 8423-8427
93. Feng W.H., Hong G., Delecluse H.J., and Kenney S.C. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J. Virol. 78 (2004) 1893-1902
94. Shugar D. Viral and host-cell protein kinases: enticing antiviral targets and relevance of nucleoside, and viral thymidine, kinases. Pharmacol. Ther. 82 (1999) 315-335
95. Koszalka G.W., Chamberlain S.D., Harvey R.J., Frick L.W., Good S.S., Davis M.L., Smith A., Drach J.C., Townsend L.B., and Biron K.K. Benzimidazoles for the treatment of human cytomegalovirus. Antivir. Res. 30 (1996) A43
96. Townsend L.B., Gudmundsson K.S., Daluge S.M., Chen J.J., Zhu Z., Koszalka G.W., Boyd L., Chamberlain S.D., Freeman G.A., Biron K.K., and Drach J.C. Studies designed to increase the stability and antiviral activity (HCMV) of the active benzimidazole nucleoside, TCRB. Nucleosides Nucleotides 18 (1999) 509-519
97. Biron K.K., Harvey R.J., Chamberlain S.C., Good S.S., Smith III A.A., Davis M.G., Talarico C.L., Miller W.H., Ferris R., Dornsife R.E., Stanat S.C., Drach J.C., Townsend L.B., and Koszalka G.W. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole l-riboside with a unique mode of action. Antimicrob. Agents Chemother. 46 (2002) 2365-2372
98. Williams S.L., Hartline C.B., Kushner N.L., Harden E.A., Bidanset D.J., Drach J.C., Townsend L.B., Underwood M.R., Biron K.K., and Kern E.R. In vitro activities of benzimidazole d- and l-ribonucleosides against herpesviruses. Antimicrob. Agents Chemother. 47 (2003) 2186-2192
99. Zacny V.L., Gershburg E., Davis M.G., Biron K.K., and Pagano J.S. Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole. J. Virol. 73 (1999) 7271-7277
100. McSharry J.J., McDonough A., Olson B., Talarico C., Davis M., and Biron K.K. Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole l-riboside 1263W94. Clin. Diagn. Lab. Immunol. 8 (2001) 1279-1281
101. Drew W.L., Miner R.C., Marousek G.I., and Chou S. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J. Clin. Virol. 37 (2006) 124-127
102. Chou S., Wechel L.C., and Marousek G.I. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. J. Infect. Dis. 196 (2007) 91-94
103. Chou S., Marousek G.I., Senters A.E., Davis M.G., and Biron K.K. Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. J. Virol. 78 (2004) 7124-7130
104. Komazin G., Ptak R.G., Emmer B.T., Townsend L.B., and Drach J.C. Resistance of human cytomegalovirus to the benzimidazole l-ribonucleoside maribavir maps to UL27. J. Virol. 77 (2003) 11499-11506
105. Lalezari J.P., Aberg J.A., Wang L.H., Wire M.B., Miner R., Snowden W., Talarico C.L., Shaw S., Jacobson M.A., and Drew W.L. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob. Agents Chemother. 46 (2002) 2969-2976
106. Lorenzi P.L., Landowski C.P., Brancale A., Song X., Townsend L.B., Drach J.C., and Amidon G.L. N-methylpurine DNA glycosylase and 8-oxoguanine DNA glycosylase metabolize the antiviral nucleoside 2-bromo-5,6-dichloro-1-(beta-d-ribofuranosyl)benzimidazole. Drug Metab. Dispos. 34 (2006) 1070-1077
107. Ma J.D., Nafziger A.N., Villano S.A., Gaedigk A., and Bertino Jr. J.S. Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob. Agents Chemother. 50 (2006) 1130-1135
108. Swan S.K., Smith W.B., Marbury T.C., Schumacher M., Dougherty C., Mico B.A., and Villano S.A. Pharmacokinetics of maribavir, a novel oral anticytomegalovirus agent, in subjects with varying degrees of renal impairment. J. Clin. Pharmacol. 47 (2007) 209-217
109. Wang L.H., Peck R.W., Yin Y., Allanson J., Wiggs R., and Wire M.B. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. 47 (2003) 1334-1342
110. Slater M.J., Cockerill S., Baxter R., Bonser R.W., Gohil K., Gowrie C., Robinson J.E., Littler E., Parry N., Randall R., and Snowden W. Indolocarbazoles: potent, selective inhibitors of human cytomegalovirus replication. Bioorg. Med. Chem. 7 (1999) 1067-1074
111. Zimmermann A., Wilts H., Lenhardt M., Hahn M., and Mertens T. Indolocarbazoles exhibit strong antiviral activity against human cytomegalovirus and are potent inhibitors of the pUL97 protein kinase. Antivir. Res. 48 (2000) 49-60
112. Marschall M., Stein-Gerlach M., Freitag M., Kupfer R., van Den Bogaard M., and Stamminger T. Inhibitors of human cytomegalovirus replication drastically reduce the activity of the viral protein kinase pUL97. J. Gen. Virol. 82 (2001) 1439-1450
113. Herget T., Freitag M., Morbitzer M., Kupfer R., Stamminger T., and Marschall M. Novel chemical class of pUL97 protein kinase-specific inhibitors with strong anticytomegaloviral activity. Antimicrob. Agents Chemother. 48 (2004) 4154-4162
114. Cohen M.H., Williams G.A., Sridhara R., Chen G., and Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 8 (2003) 303-306
115. Mett H., Holscher K., Degen H., Esdar C., De Neumann B.F., Flicke B., Freudenreich T., Holzer G., Schinzel S., Stamminger T., Stein-Gerlach M., Marschall M., and Herget T. Identification of inhibitors for a virally encoded protein kinase by 2 different screening systems: in vitro kinase assay and in-cell activity assay. J. Biomol. Screen. 10 (2005) 36-45
116. Frame M.C., Purves F.C., McGeoch D.J., Marsden H.S., and Leader D.P. Identification of the herpes simplex virus protein kinase as the product of viral gene US3. J. Gen. Virol. 68 Pt 10 (1987) 2699-2704
117. Chung T.D., Wymer J.P., Smith C.C., Kulka M., and Aurelian L. Protein kinase activity associated with the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10). J. Virol. 63 (1989) 3389-3398
118. Ng T.I., Ogle W.O., and Roizman B. UL13 protein kinase of herpes simplex virus 1 complexes with glycoprotein E and mediates the phosphorylation of the viral Fc receptor: glycoproteins E and I. Virology 241 (1998) 37-48
119. Ogle W.O., Ng T.I., Carter K.L., and Roizman B. The UL13 protein kinase and the infected cell type are determinants of posttranslational modification of ICP0. Virology 235 (1997) 406-413
120. Ogle W.O., and Roizman B. Functional anatomy of herpes simplex virus 1 overlapping genes encoding infected-cell protein 22 and US1.5 protein. J. Virol. 73 (1999) 4305-4315
121. Bruni R., Fineschi B., Ogle W.O., and Roizman B. A novel cellular protein, p60, interacting with both herpes simplex virus 1 regulatory proteins ICP22 and ICP0 is modified in a cell-type- specific manner and Is recruited to the nucleus after infection. J. Virol. 73 (1999) 3810-3817
122. Long M.C., Leong V., Schaffer P.A., Spencer C.A., and Rice S.A. ICP22 and the UL13 protein kinase are both required for herpes simplex virus-induced modification of the large subunit of RNA polymerase II. J. Virol. 73 (1999) 5593-5604